David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, United States.
Bioconjug Chem. 2020 Mar 18;31(3):462-473. doi: 10.1021/acs.bioconjchem.9b00828. Epub 2020 Feb 11.
In recent years, therapeutic conjugates have attracted considerable attention as a new class of drug due to their unique pharmacological properties, especially from the pharmaceutical community. Their molecular structure tunability, improved targeting specificity, and therapeutic efficacy have been demonstrated in a wide range of research and clinical applications. In this topical review, we summarize selected recent advances in bioconjugation strategies for the development of therapeutic conjugates, their emerging application in clinical settings, as well as perspectives on the direction of future research.
近年来,治疗性偶联物因其独特的药理学特性而引起了相当大的关注,尤其是在制药界。它们的分子结构可调节性、提高的靶向特异性和治疗效果已在广泛的研究和临床应用中得到证实。在这篇专题评论中,我们总结了用于开发治疗性偶联物的生物偶联策略的一些最新进展、它们在临床环境中的新兴应用以及对未来研究方向的看法。